We would love you to join us for a virtual event on Monday 24 March as Kilburn & Strode’s patent experts reflect on some of the most influential case law that emerged from the EPO last year while identifying some key take-away practice points.
This year’s review includes:
-
An update on the continually evolving case law on post-filed data following the landmark "plausibility" decision, G 2/21. We review how the Boards of Appeal have been applying this decision in practice, and how applicants can put themselves in the best possible position to have their vital data considered by the EPO.
-
Following on from G 1/22's "rebuttable presumption" of priority, we discuss the outcome of the consolidated appeal on the Broad Institute's European platform patents for CRISPR/Cas9 and what this means for patent proprietors and opponents.
-
Disclosure of machine learning models: we discuss the EPO’s recent guidance on ensuring AI-based patent applications meet the bar for sufficiency of disclosure.
-
Medical use claims: we consider what products qualify as a “substance or composition” required for a medical use claim and whether a therapeutic effect must be achieved by means of a chemical interaction in the body.
-
Appeal strategy: we provide practical tips for patent proprietors and opponents on maximising their chances for a successful appeal by avoiding admissibility pitfalls under the strict rules of procedure of the Boards of Appeal.
We hope you can join us!